Chanice Henry | 08/08/2017
Experts have urged that legislation on early access programs needs to be tightened to protect the seriously ill Through expanded early access programs (EAPs), terminally- ill patients that fit certain criteria will be allowed access to unauthorized drugs outside of a clinical trial.These programs aim to give dying patients ethical and controlled strategic access to potentially life- saving medicines before they gain approval. However, the lack of clarity and harmonization of regional regul...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
DigIT Pharma AI Commercial Excellence & Health 2025
September 01 - 03, 2025
Palace Hotel Berlin, Germany
Register Now |
View Agenda |
Learn More

AI for Pharma & Healthcare
23 - 25 September, 2025
Amsterdam
Register Now |
View Agenda |
Learn More
